• Explore /
  • Poster
  • / Pazopanib and 5-FU/oxaliplatin as first-line treatment in advanced gastric cancer: PaFLO, a randomized phase II study from the AIO (Arbeitsgemeinschaft Internistische Onkologie).

Pazopanib and 5-FU/oxaliplatin as first-line treatment in advanced gastric cancer: PaFLO, a randomized phase II study from the AIO (Arbeitsgemeinschaft Internistische Onkologie).

Abstract Poster

Authors

null

Peter C. Thuss-Patience

Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Med Klinik m. S. Hämatologie, Onkologie u. Tumorimmunologie, Berlin, Germany

Peter C. Thuss-Patience , Salah-Eddin Al-Batran , Jens T Siveke , Nils Homann , Peter Malfertheiner , Dietrich Glaeser , Alexander Stein , Ingo Tamm , Severin Daum , Jochem Potenberg , Axel Florschütz , Arndt Vogel , Karsten Ridwelski , Matthias Ritgen , Michael Geissler , Harald Schmalenberg , Peter Schlattmann , Mario Lorenz , Kirstin Breithaupt , Uwe Pichlmeier

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT01503372

Citation

J Clin Oncol 33, 2015 (suppl; abstr 4033)

DOI

10.1200/jco.2015.33.15_suppl.4033

Abstract #

4033

Poster Bd #

142

Abstract Disclosures

Similar Posters

First Author: Kirstin Breithaupt

First Author: Yelena Y. Janjigian

First Author: Rongbo Lin

First Author: Ryan Sugarman